Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 DDI with LNG/EE
NCT06783192Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mk-8527 in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Area under the curve from dosing to infinity of levonorgestrel, Maximum plasma concentration of levonorgestrel and 4 more. Started Aug 2023; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06783192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783192.